Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 7 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ibrutinib for chronic Graft versus Host Disease Ibrutinib (Imbruvica) Graft versus host disease (GvHD) Immunology 2020 View  |  Download
Ibrutinib for the treatment of relapsed or refractory follicular lymphoma Ibrutinib (Imbruvica) Follicular lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib in addition to rituximab for chronic lymphocytic leukaemia – first-line Ibrutinib (Imbruvica) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2019 View  |  Download
Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line Ibrutinib (Imbruvica) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib in combination with venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma – first line Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2020 View  |  Download
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia Ibrutinib (Imbruvica) , Ublituximab (TG-1101; LFB-R603) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2018 View  |  Download
Venetoclax in addition to ibrutinib for relapsed mantle cell lymphoma – second-line and beyond Ibrutinib (Imbruvica) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Mantle cell lymphoma Haematological Cancer and Lymphomas 2020 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications